| Filed On | Filing |
|---|---|
| 09 Nov 2026 |
8-K/A: Costs Associated with Exit or Disposal Activities
On October 27, 2026, Artiva Biotherapeutics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original 8-K”) with the Securities and Exchange Commission (the “SEC”) disclosing that the Company’s board of directors approved t... |
| 09 Nov 2026 | 10-Q |
| 03 Nov 2026 |
Form 4: Horan Christopher, Chief Tech Operations Officer
Sold 10,423 shares ($43.6K) |
| 03 Nov 2026 |
Form 4: Bush Jennifer, COO, CLO, Compliance Officer
Sold 8,439 shares ($35.3K) |
| 03 Nov 2026 |
Form 4: Banerjee Subhashis, Chief Medical Officer
Sold 1,110 shares ($4.64K) |
| 03 Nov 2026 |
Form 4: Aslan Fred, Director
Sold 62,178 shares ($260K) |
| 27 Oct 2026 |
8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial |
| 07 Oct 2026 |
Form 4: Aslan Fred, Director
Sold 23,463 shares ($169K) |
| 06 Oct 2026 | 144 |
| 06 Oct 2026 |
Form 4: Horan Christopher, Chief Tech Operations Officer
Sold 10,340 shares ($70.7K) |
| 06 Oct 2026 |
Form 4: Bush Jennifer, COO, CLO, Compliance Officer
Sold 8,370 shares ($57.2K) |
| 06 Oct 2026 |
Form 4: Banerjee Subhashis, Chief Medical Officer
Sold 1,099 shares ($7.51K) |
| 06 Oct 2026 |
Form 4: Aslan Fred, Director
Sold 61,696 shares ($422K) |
| 15 Sep 2026 |
Form 4: Aslan Fred, Director
Received 110,000 shares as a grant or award · Granted 315,000 Employee Stock Option (Right to Buy) |
| 14 Sep 2026 |
Form 4: Aslan Fred, Director
Received 45,000 shares as a grant or award · Granted 155,000 Employee Stock Option (Right to Buy) |
| 14 Sep 2026 |
Form 4: Ra Capital MANAGEMENT, L.p., Director and 5 others
Granted 16,250 Director Stock Option (Right to Buy) |
| 14 Sep 2026 |
Form 4: Stoppel Laura, Director
Granted 16,250 Director Stock Option (Right to Buy) |
| 14 Sep 2026 |
Form 4: Sorg Elaine K., Director
Granted 16,250 Director Stock Option (Right to Buy) |
| 14 Sep 2026 |
Form 4: Hougen Elizabeth L, Director
Granted 16,250 Director Stock Option (Right to Buy) |
| 14 Sep 2026 |
Form 4: Daniels Brian, Director
Granted 16,250 Director Stock Option (Right to Buy) |
Loading...